InsiderTrades.com logo
Election warning coming true…
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.

Robert Waltermire Biography and Net Worth

VP of Madrigal Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Dr. Robert E. Waltermire Ph.D. is the Chief Pharmaceutical Devel. Officer at Madrigal Pharmaceuticals Inc.

What is Robert E. Waltermire's net worth?

The estimated net worth of Robert E. Waltermire is at least $1.75 million as of June 14th, 2024. Dr. Waltermire owns 5,500 shares of Madrigal Pharmaceuticals stock worth more than $1,752,795 as of December 3rd. This net worth approximation does not reflect any other investments that Dr. Waltermire may own. Learn More about Robert E. Waltermire's net worth.

How do I contact Robert E. Waltermire?

The corporate mailing address for Dr. Waltermire and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Robert E. Waltermire's contact information.

Has Robert E. Waltermire been buying or selling shares of Madrigal Pharmaceuticals?

Robert E. Waltermire has not been actively trading shares of Madrigal Pharmaceuticals over the course of the past ninety days. Most recently, Robert E. Waltermire sold 1,900 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $280.00, for a transaction totalling $532,000.00. Following the completion of the sale, the vice president now directly owns 5,500 shares of the company's stock, valued at $1,540,000. Learn More on Robert E. Waltermire's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 1 times. They purchased a total of 81,159 shares worth more than $17,805,473.01. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 192,984 shares worth more than $42,696,222.98. The most recent insider tranaction occured on November, 25th when Director Fred B Craves sold 3,400 shares worth more than $1,191,020.00. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 11/25/2024.

Robert E. Waltermire Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2024Sell1,900$280.00$532,000.005,500View SEC Filing Icon  
6/12/2024Sell2,000$285.00$570,000.005,500View SEC Filing Icon  
5/21/2024Sell1,036$231.34$239,668.245,500View SEC Filing Icon  
12/13/2023Sell2,500$225.40$563,500.005,667View SEC Filing Icon  
See Full Table

Robert E. Waltermire Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Robert E Waltermire's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $318.69
Low: $315.64
High: $322.85

50 Day Range

MA: $264.17
Low: $202.48
High: $354.85

2 Week Range

Now: $318.69
Low: $168.25
High: $368.29

Volume

84,813 shs

Average Volume

439,848 shs

Market Capitalization

$6.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Election warning coming true…
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.